Leritrelvir for COVID-19: real-time analysis of 5 studies

c19early.org
Leritrelvir for COVID-19
3 studies with >2,000 patients
Significantly lower risk for recovery and viral clearance.
3 studies from 3 independent teams (all from the same country) show significant benefit.
COVID-19 Leritrelvir studies · November 2026
Leritrelvir was adopted in 1 country. Recent:
Cheng.
Covid Analysis Leritrelvir reduces COVID-19 risk: real-time meta-analysis of 3 studies (Version 2)
Significantly lower risk is seen for recovery and viral clearance. 3 studies from 3 independent teams (all from the same country) show significant benefit. Meta-analysis using the most serious outcome reported shows 30% [10‑46%..
Oct 31
Cheng et al., Journal of Thoracic Disease, doi:10.21037/jtd-2026-2569 Effects of leritrelvir for adults with mild-to-moderate coronavirus disease 2019: A multicenter real-world study
40% improved recovery (p<0.0001) and 18% improved viral clearance (p=0.04). Prospective study of 1,527 adults with mild-to-moderate COVID-19 showing faster sustained symptom resolution with leritrelvir. There were no deaths or progression to severe COVID-19.
Jul 6
2024
Zhao et al., Quantitative Biology, doi:10.1002/qub2.60 Assessing the inhibition efficacy of clinical drugs against the main proteases of SARS‐CoV‐2 variants and other coronaviruses
In vitro study showing that leritrelvir and GC376 remained effective against some nirmatrelvir- and ensitrelvir-resistant Mpro mutants. Leritrelvir showed better broad-spectrum activity against other pathogenic coronaviruses compared to e..
Mar 29
2024
Chen et al., Nature Microbiology, doi:10.1038/s41564-024-01618-9 Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir
In vitro and K18-hACE2 transgenic mouse study showing the preclinical efficacy of RAY1216, an inhibitor of the SARS-CoV-2 main protease (Mpro), against multiple SARS-CoV-2 variants. RAY1216 forms a covalent bond with the catalytic cystein..
Jan 31
2024
Zhan et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.102359 Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial
17% improved recovery (p=0.002) and 16% improved viral clearance (p=0.01). RCT 1,359 COVID-19 outpatients showing faster recovery with leritrelvir monotherapy (without ritonavir), 251 vs. 271 hours, and improved viral clearance. There were no significant differences in adverse events between groups.
Sep 30
2023
Wang et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.102189 Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial
35% faster recovery (p=0.04) and 21% improved viral clearance (p=0.01). RCT 60 hospitalized COVID-19 patients in China showing imporoved recovery and viral clearance with RAY1216, a 3CLpro inhibitor.